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Objectives: To determine the predictors of testosterone recovery after 
termination of androgen deprivation therapy in high/intermediate-risk 
prostate cancer patients receiving external beam radiation therapy with 
neoadjuvant and adjuvant androgen deprivation therapy. 
Methods: A total of 82 patients who underwent external beam radiation 
therapy with androgen deprivation therapy for prostate cancer were 
retrospectively analyzed. Serum testosterone levels after androgen 
deprivation therapy terminations were studied. Cox proportional hazard 
models and the Kaplan–Meier method were used for statistical analysis. 
Results: Median age, baseline testosterone, nadir testosterone and duration 
of androgen deprivation therapy were 73 years, 456 ng/dL, 16 ng/dL and 26 
months, respectively. Androgen deprivation therapy duration of 33 months 
(hazard ratio 0.13; P = 0.0018), nadir testosterone of 20 ng/dL (hazard ratio 
0.35; P = 0.0112) and testosterone >50 ng/dL at 6 months after androgen 
deprivation therapy termination (hazard ratio 0.21; P = 0.0075) were 
significantly associated with testosterone recovery to normal levels (200 
ng/dL) on multivariate analysis. Androgen deprivation therapy duration of 
33 months (hazard ratio 0.31; P = 0.0023) and nadir testosterone of 20 
ng/dL (hazard ratio 0.38; P = 0.0012) were significantly associated with 
testosterone recovery to the supracastrate level (50 ng/dL) on multivariate 
analysis. After dividing patients into three risk groups, the rate of 
testosterone recovery to the normal level after 2 years of androgen 
deprivation therapy termination was 100% in the low-risk group versus 
20.8% in the high-risk group (P < 0.0001); the rate of testosterone recovery 
to the supracastrate level was 100% in the low-risk group versus 51.5% in 
the high-risk group (P < 0.0001). 
Conclusions: Duration of androgen deprivation therapy and achievement 
of nadir testosterone 20 ng/dL both predict testosterone recovery to the 
supracastrate level in prostate cancer patients undergoing external beam 
radiation therapy with androgen deprivation therapy. 
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Introduction 
ADT is a well-established therapy for patients with metastatic PC. (1, 2) 
ADT is used in radiotherapy for the management of PC. Past studies 
showed that the use of ADT with EBRT improved overall survival or 
cancer-specific survival of patients with PC compared with EBRT alone. A 
total of 4–6 months of ADT combined with EBRT was an effective 
treatment for intermediate-risk PC, (3–6) whereas 2–3 years of ADT 
combined with EBRT was recommended to manage high-risk PC. (7–9) 
With regard to ADT, we have recently reported the clinical significance of 
attaining a TST level of 20 ng/dL during combined androgen blockade. (10) 
Klotz et al. also reported that a low nadir testosterone (<20 ng/dL) within 
the first year of ADT correlated with improved cause-specific survival. (11) 
These data showed the clinical significance of monitoringTST levels during 
ADT in PC patients.  
Although combined ADT with EBRT is standard therapy in intermediate 
and high-risk PC patients, we have limited evidence related to the shift of 
TST levels during and after treatment. (6) For instance, in assessing 
biochemical recurrencefree survival in patients who received combined 
ADT with EBRT, it is desirable to discriminate patients who do not relapse 
after recovery of TST or patients who do not relapse due to the 
supracastrated level of TST. If we can predict the recovery of TST in 
individual patients, we might be able to more objectively assess 
biochemical recurrence in patients who received ADT with EBRT. In 
addition, recovery of the TST level is critical in those who receive 
intermittent ADT. Furthermore, we might even temporarily terminate 
long-term ADT in those who are expected to remain castrate, especially in 
those with low-performance status or elderly patients. 
In the current study, the predictors of TST recovery were assessed after 
termination of ADT in high/intermediate-risk PC patients receiving EBRT 
with neoadjuvant and adjuvant ADT. The current data might provide 
evidence of not only TST recovery, but also when to terminate long-term 
ADT without harming castration levels in PC patients.
Methods 
A total of 82 Japanese patients who received EBRT with ADT using a 
LHRH agonist for high- and intermediate-risk PC at Chiba University 
Graduate School of Medicine Hospital, Chiba City, Chiba, Japan, from 
2003 to 2016 were retrospectively enrolled in this study. Intermediate-risk 
patients received neoadjuvant ADT only, and high-risk patients received 
both neoadjuvant and adjuvant ADT. Neoadjuvant ADT was given for 6 
months, and adjuvant ADT was given for 2 years. Some of the very 
high-risk PC patients received over 3 years of ADT based on their doctor’s 
decision. Leuprorelin or goserelin was used as the LHRH agonist. A total of 
76 patients took bicalutamide 80 mg every day with the LHRH agonist. 
The EBRT dose was 72 Gy by 3DCRT. The serum TST levels were mainly 
measured every 3 months, with some exception based on the individual 
follow-up periods and follow-up protocol. We studied TST levels after 
termination of ADT in association with other clinical factors, including 
ADT duration, age, PSA level and nadir TST level. A TST of >50 ng/dL 
was defined as the supracastrate level, and a TST of >200 ng/dL was 
defined as the normal level. We used receiver operating characteristic 
analysis for the cut-off point of other predictive factors. 
 Architect Testosterone II (Abbot Diagnostics, Lake Forest, IL, USA) was 
used to determine serum testosterone levels. We evaluated TST recovery to 
the supracastration level (TST >50 ng/dL) and normal level (TST >200 
ng/dL) according to the risk criteria based on the independent predictive 
factors. 
 
Compliance with ethical standards  
The current study was approved by the institutional review board (approval 
number 2252).  
 
Statistical analysis  
The Kaplan–Meier method was used for statistical analysis, and the log–
rank test was used to compare these estimates. Univariate and multivariate 
Cox proportional hazard models were used to estimate the cumulative 
incidence of TST recovery. P-values <0.05 were considered significant. 
JMP pro 12.0.1 software (SAS Institute, Cary, NC, USA) was used for all 
analyses.
Results 
The median (range), age, initial PSA, initial TST and nadir TST were 73 
years (64–85 years), 17.57 ng/mL (4.49–425 ng/mL), 456 ng/mL (146–
1079 ng/mL) and 16 ng/mL (1–71 ng/mL), respectively. The median dose 
of radiation therapy was 72 Gy. As the LHRH agonists, leuprorelin and 
goserelin were used by 52 patients (63.4%) and 30 patients (36.6%), 
respectively. The median duration of ADT was 26 months (4–95 months), 
and follow-up duration was 49 months (9–128 months; Table 1). 
Figure 1 shows the TST levels of each patient after termination of ADT. 
This figure shows that there were two patterns of TST recovery. One was 
rapid recovery to a normal TST level by 6–12 months. The other was 
non-recovery to a normal TST level over the long term. 
On univariate Cox proportional hazard analysis, ADT duration≥33 
months (ADT ≥33 months; HR 0.16; P < 0.0001), TST nadir level ≤20 
ng/dL (HR 0.22; P < 0.0001), TST ≤50 ng/dL 6 months after termination of 
ADT (TST 6 months ≤50 ng/dL; HR 0.18; P < 0.0001) and age >70 years 
(HR 0.42; P = 0.0048) were significant factors associated with TST 
recovery to the normal level (200 ng/dL). On multivariate analysis, ADT 
≥33 months (HR 0.13; P = 0.0018), nadir TST level ≤20 ng/dL (HR 0.35; P 
= 0.0112) and TST 6 months ≤50 ng/dL (HR 0.21; P = 0.0075) were 
significant factors associated with TST recovery (Table 2). ADT ≥33 
months, TST nadir level ≤20 ng/dL and TST 6 months ≤50 ng/dL were also 
significant factors in the log–rank test (P < 0.0001; Fig. 2a–c). 
Next, ADT ≥33 months, TST nadir level ≤20 ng/dL and TST 6 months 
≤50 ng/dL were defined as the risk factors, and TST recovery to normal 
levels was analyzed based on the number of risk factors. Figure 3 shows 
the Kaplan–Meier analysis of TST recovery to the normal level (200 ng/dL) 
after termination of ADT by the risk factor values, low risk = score 0, 
intermediate risk = score 1 and high risk = score 2–3. The TST recovery 
rates to the normal level 2 years after termination of ADT in the low-, 
intermediateand high-risk groups were 100%, 78.8% and 20.8%, 
respectively, and 5 years after termination of ADT they were 100%, 89.4% 
and 26.9%, respectively (low vs intermediate risk P = 0.0049; intermediate 
vs high risk P < 0.0001;Fig. 3). 
On univariate Cox proportional hazard analysis, ADT ≥33 months (HR 
0.22; P < 0.0001), TST nadir level ≤20 ng/dL (HR 0.28; P < 0.0001) and 
initial PSA >36.16 ng/mL (HR 0.52; P = 0.0364) were significant factors 
associated with TST recovery to supracastrate level (TST >50 ng/dL). On 
multivariate analysis, ADT ≥33 months (HR 0.31; P = 0.0023) and TST 
nadir level ≤20 ng/dL (HR 0.38; P = 0.0012) were significant factors 
associated with TST recovery to the supracastrate level (Table 3). ADT ≥33 
months and TST nadir level ≤20 ng/dL were also significant factors in the 
log–rank test (P < 0.0001; Fig. 4a,b).  
Androgen deprivation therapy ≥33 months and TST nadir level ≤20 
ng/dL were defined as the risk factors, and TST recovery to supracastrate 
level was analyzed by the number of risk factors. Figure 3 shows the 
Kaplan–Meier analysis of TST recovery to supracastrate level (50 ng/dL) 
after termination of ADT by the number of risk factors, low risk = score 0, 
intermediate risk = score 1 and high risk = score 2. The TST recovery rates 
to the supracastrate level 2 years after termination of ADT in the low-, 
intermediate- and high-risk groups were 100%, 90.9%, and 51.5%, 
respectively, and 5 years after termination of ADT, they were 100%, 100% 
and 63.4%, respectively (low vs intermediate risk P = 0.0014; intermediate 
vs high risk P < 0.0001; Fig. 5). 
Between leuprorelin and goserelin, there were no significant differences 
in TST recovery to both the supracastrate level (>50 ng/dL; P = 0.8581) 
and the normal level (>200 ng/dL; P = 0.6661; Fig. 6). 
Discussion 
The present study identified that a nadir TST of ≥20 ng/dL and ADT 
duration of ≤33 months were useful as markers for predicting TST recovery 
to the supracastrate level in PC patients that received EBRT with ADT. 
Furthermore, TST of <50 ng/dL at 6 months after termination of ADT 
predicted reduced TST recovery to the normal level (>200 ng/dL). Based 
on three factors, (i) nadir TST, (ii) duration of ADT and (iii) TST 50 ng/dL 
at 6 months after ADT, it might also be possible to assess the trends of TST 
recovery in PC patients who receive EBRT with ADT. 
Past studies showed that the predictive factors of TST recovery after 
termination of ADT were ADT duration and age. (12–14) By carrying out 
testicular biopsies in PC patients who received long-term ADT, Giberti et al. 
reported that long-term ADT impaired Leydig cell masses with tubular 
derangement and fibrosis. (15) Long-term ADT induces not only functional 
inhibition of testicular androgenesis, but also anatomical testicular damage 
that is likely irreversible. Egawa et al. reported that patients who 
maintained castrate TST levels after termination of long-term ADT had 
above normal luteinizing hormone levels. (13) This is considered to occur 
because the feedback system of the hypothalamic–pituitary axis responded 
normally to the low TST levels after termination of ADT. Past studies 
reported that older age was a significant factor associated with slower TST 
recovery. (14, 16, 17) Other studies showed that the production of TST 
decreases with age. (18, 19) This decline might be related to later TST 
recovery in older men treated with ADT. In the present study, age was a 
significant predictive factor in the univariate analysis. Even if we confirm 
age as a continuous variable, the result was consistent (Table S1). However, 
age failed to remain as an independent factor in multivariate analysis. This 
result might indicate that the predictive ability of other variables including 
nadir TST and duration of ADT had more significant predictive ability 
compared with that of age, in the case of TST recovery after termination of 
ADT. 
With regard to the direct effect of radiation on TST levels, some studies 
showed the impact of scatter radiation on TST levels and Leydig cell 
function. (20–22) Zagars et al. reported that the mean percentage decrease 
of TST after 68-Gy EBRT for localized PC was 9%. (21) Pickles et al. 
reported that the mean percentage decrease of TST 6 months after 68-Gy 
EBRT for localized PC was 17% and recovery of TST typically 
occurred 18 months after EBRT. (22) Tsumura et al. reported TST recovery 
after termination of long-term ADT with prostate brachytherapy, and they 
found that TST at the termination of ADT predicted TST recovery. (16) It is 
not clear how brachytherapy influences TST levels, but TST recovery after 
termination of ADT depends mainly on ADT duration, independent of the 
type of radiation therapy.  
ADT has significant adverse effects, including hot flushes, decreased 
libido, loss of bone density and muscles, and possible cardiovascular events. 
The decrease in testosterone due to ADT results in both loss of libido and a 
decrease in erectile function. Erectile dysfunction was reported to be 
induced by venous leakage, decreased arterial flow and impaired nitric 
oxide under the reduced TST environment. (23) 
The European Organization for Research and Treatment of Cancer 
carried out a non-inferiority trial of radiation plus 6 versus 36 months ADT 
in men with high-risk to locally advanced PC. They found a significant 
improvement in sexual function and activity with the shorter course of 
ADT (P < 0.001), but there was also a significant increase in mortality (HR 
for death 1.42; 95.71% CI 1.09–1.85). (9) Although there was no direct 
quality of life comparison between 18 and 36 months of ADT, the 
TROG03-04 trial randomized men to 6 versus 18 months of ADT and 
found that, in the 18-month arm of ADT, sexual activity was worse at 18 
months, but not significantly worse by 36 months. (24) In the present data, 
the TST recovery rate to normal level 2 years after termination of ADT was 
100% in low-risk patients, whereas that of high-risk patients was 20.8%. 
Although the rate of TST recovery is low in high-risk patients, the present 
study provided novel evidence showing that, by examining TST recovery 
to 50 ng/dL at 6 months after termination of ADT, one can predict the 
recovery of TST to the normal level. In contrast, when we examined the 
patients that received >3 years of ADT, TST recovery at 6 months and nadir 
TST failed to predict the TST recovery to a normal level (Table S2). This 
evidence might indicate serious damage in the testicular function of TST 
production after >3 years of ADT. 
With regard to the limitations of the present study, first, it only analyzed 
a small number of patients in a retrospective manner. A large number of 
patients need to be studied prospectively to accurately determine the 
predictors for TST recovery after ADT. Second, serum TST levels were 
mainly measured every 3 months; however, the intervals were different for 
some of the patients. The difference in measurement time-point might 
affect the result of TST recovery. The current result will need to confirmed 
in a prospective manner. Third, the type of EBRT was only 3DCRT. 
Recently, the number of PC patients who receive intensity-modulated 
radiation therapy has been increasing. We are currently investigating the 
difference in TST recovery between 3DCRT and intensity-modulated 
radiation therapy. Fourth, only LHRH agonists were used for ADT in the 
present study. We are currently investigating the difference in TST recovery 
between LHRH agonist and LHRH antagonist treatment. 
In conclusion, nadir TST of 20 ng/dL and duration of ADT predict TST 
recovery to the supracastrate level in PC patients who received EBRT. The 
current data described the significance of not only the duration of hormonal 
therapy, but also monitoring the nadir TST level to predict TST recovery in 
patients receiving combined EBRT with ADT. 
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Table 1. Patients’ characteristics (n=82)
Clinical Factors Median (Range)　or number (%)
Age (y) 73 (64-85)
BMI (kg/m2) 23.59 (19.47-32.27)
Initial PSA (ng/ml) 17.57 (4.49-425)
GS sum       6 8 (10%)
7 47 (58.8%)
8 17 (21.3%)
9 8 (10%)
ADT duration (months) 26 (4-95)
Adjuvant ADT 61 (74.4%)
Leuprorelin/goserelin 52 (63.4%) / 30 (36.6%)
Initial TST (ng/dL) 456 (146-1079)
Nadir TST (ng/dL) 16 (1-71)
Follow up duration (M) 49 (9-128)
BMI: Body mass index, PSA: Prostate specific antigen, GS: Gleason score, ADT: Androgen deprivation therapy,
TST: Testosterone
Figure1 
 
Fig. 1 TST levels after termination of ADT. There are two patterns of TST 
recovery. One is rapid recovery to a normal TST level by 6–12 months. The 
other is non-recovery to a normal TST level over the long term. 
 
Table 2. TST recovery to normal level (200 ng/dL) after termination of ADT on cox proportional hazard analysis.
HR(95% CI) P HR(95% CI) P
ADT total duration≥ 33 months 0.16(0.05-0.35) <0.0001 0.13(0.02-0.50) 0.0018
TST≤ 50 ng/dL (6moths post ADT) 0.18(0.08-0.36) <0.0001 0.21(0.06-0.67) 0.0075
Nadir TST ≤ 20 ng/dL 0.22(0.11-0.43) <0.0001 0.35(0.14-0.79) 0.0112
Age at ADT off> 70 years 0.42(0.23-0.76) 0.0048 0.60(0.22-1.57) 0.3012
Initial PSA> 36.16 ng/ml 0.47(0.21-0.99) 0.0471 0.75(0.21-2.24) 0.6271
Leuprorelin (vs goserelin) 1.22(0.64-2.43) 0.5439
Initial TST≤ 456ng/dL 0.64(0.31-1.31) 0.2219
Gleason score≥ 8 0.69(0.30-1.39) 0.3157
BMI> 23.59 kg/m2 0.70(0.27-1.86) 0.469
Univariate analysis Multivariate analysis
TST > 50 ng/dL (6 months post ADT): TST> 50 ng/dL at 6 months after termination of ADT, Age at ADT off: Age when the
patient stopped ADT, ADT: Androgen deprivation therapy, TST: Testosterone, PSA: Prostate specific antigen, BMI: Body
mass index
Figure2 
 
Fig. 2 Kaplan–Meier analysis of (a) TST recovery to a normal level (200 
ng/dL) after termination of ADT by nadir TST level 20 ng/dL (nTST 20 
ng/dL), (b) ADT duration 33 months (ADT 33 m) and (c) TST 50 ng/dL 6 
months after termination of ADT (TST 50 ng/dL [6 m post-ADT]). 
Figure3 
 
Fig. 3 Kaplan–Meier analysis of TST recovery to a normal level (200 
ng/dL) after termination of ADT by the risk factor score (low risk = score 0, 
intermediate risk = score 1 and high risk = score 2–3). ADT ≥33 months, 
TST ≤20 ng/dL and TST 6 months ≤50 ng/dL are the risk factors. 
 
Figure4 
 
Fig. 4 Kaplan–Meier analysis of (a) TST recovery to supracastrate level 
(>50 ng/dL) after termination of ADT by nadir TST level 20 ng/dL (nTST 
20 ng/dL) and (b) ADT duration 33 months (ADT 33 m).
Table 3. TST recovery to supracastrate level (50 ng/dL) after termination of ADT on cox proportional hazard analysis.
HR(95% CI) P HR(95% CI) P
ADT total duration≥33M 0.22(0.10-0.45) <0.0001 0.31(0.13-0.67) 0.0023
Nadir TST≤20ng/dL 0.28(0.16-0.48) <0.0001 0.38(0.21-0.68) 0.0012
Initial PSA>36.16ng/ml 0.52(0.26-0.96) 0.0364 0.91(0.43-1.82) 0.8141
Age at ADT off>70 0.70(0.42-1.19) 0.184
Leuprorelin (vs Goserelin) 1.12(0.65-1.97) 0.6948
Initial TST≤456ng/dL 0.88(0.49-1.61) 0.6908
Gleason score≥8 0.55(0.28-1.01) 0.0542
BMI>23.59 1.22(0.56-2.75) 0.6129
Univariate analysis Multivariate analysis
Age at ADT off: Age when the patient stopped ADT, ADT: Androgen deprivation therapy, TST: Testosterone, PSA:
Prostate specific antigen, BMI: Body mass index
Figure5 
 
Fig. 5 Kaplan–Meier analysis of TST recovery to the supracastrate level 
(>50 ng/dL) after termination of ADT by the number of risk factors (low 
risk = score 0, intermediate risk = score 1 and high risk = score 2). ADT 
≥33 months and TST nadir level ≤20 ng/dL are the risk factors. 
 
Figure6 
 
Fig. 6 Kaplan–Meier analysis by type of LHRH agonist (leuprorelin and 
goserelin). TST recovery rates to (a) the supracastrate level (TST >50 
ng/dL) and (b) normal level (TST >200 ng/dL) after termination of ADT. 
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